Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 47,308 |
|
|||||
| News | - | ||||||
| Day High | 0.6941 | Low High |
|||||
| Day Low | 0.66 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Galecto Inc | GLTO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0193 | 2.86% | 0.6948 | 17:29:07 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.675 | 0.66 | 0.6941 | 0.6801 | 0.6755 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 135 | 47,308 | US$ 0.680054 | US$ 32,172 | - | 0.50 - 3.70 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:29:07 | formt | 100 | US$ 0.6948 | USD |
Galecto Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.44M | 27.11M | - | 0 | -38.35M | -1.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Galecto News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/08/2024 | 15:29 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 3/08/2024 | 15:00 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 2/09/2024 | 14:06 | Edgar (US Regulatory) | Form SCHEDULE 13G/A - Statement of acquisition of beneficial.. |
| 1/05/2024 | 15:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 1/05/2024 | 15:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 12/21/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/06/2023 | 15:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 10/23/2023 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/03/2023 | 10:29 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 10/02/2023 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/26/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/15/2023 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLTO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.70 | 0.72 | 0.65 | 0.6874165 | 92,601 | -0.0052 | -0.74% |
| 1 Month | 0.75 | 0.79 | 0.60 | 0.7053929 | 125,128 | -0.0552 | -7.36% |
| 3 Months | 0.591 | 0.94 | 0.591 | 0.7570688 | 211,066 | 0.1038 | 17.56% |
| 6 Months | 0.53 | 0.94 | 0.50 | 0.6858035 | 283,507 | 0.1648 | 31.09% |
| 1 Year | 1.77 | 3.70 | 0.50 | 0.9848139 | 366,042 | -1.08 | -60.75% |
| 3 Years | 5.69 | 16.41 | 0.50 | 3.10 | 277,636 | -5.00 | -87.79% |
| 5 Years | 15.77 | 17.99 | 0.50 | 3.28 | 243,307 | -15.08 | -95.59% |
Galecto Description
| Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. |
